Abstract
PRAC1, which is specifically expressed in prostate, rectal, and distal colon tissues, plays a critical role in the maintenance and self-renewal of prostate epithelial stem cells. However, the role of PRAC1 in prostate cancer is unclear. In this study, we found that PRAC1 expression is upregulated in prostate cancer cells and that PRAC1 knockdown represses the proliferation of prostate cancer cells. Moreover, lysine-specific demethylase 1 (LSD1) promoted prostate cancer cell proliferation by upregulating PRAC1 expression. TAK-418, an LSD1 inhibitor, suppressed prostate cancer cell proliferation by downregulating PRAC1 expression. Our results highlight PRAC1 or LSD1 inhibition as promising avenues for prostate cancer treatment.
Data availability
The datasets generated during and/or analyzed in the current study are available from the corresponding author on reasonable request.
References
Siegel, D. A., O’Neil, M. E., Richards, T. B., Dowling, N. F. & Weir, H. K. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001–2017. MMWR Morb. Mortal. Wkly Rep. 69, 1473–1480. https://doi.org/10.15585/mmwr.mm6941a1 (2020).
Rebello, R. J. et al. Prostate cancer. Nat. Reviews Disease Primers. 7, 9. https://doi.org/10.1038/s41572-020-00243-0 (2021).
Cornford, P. et al. Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 86, 148–163. https://doi.org/10.1016/j.eururo.2024.03.027 (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG.
Liu, X. F. et al. A novel small nuclear protein that is specifically expressed in human prostate and colon. Prostate 47. PRAC, 125–131. https://doi.org/10.1002/pros.1055 (2001).
Ewing, C. M. et al. Germline mutations in HOXB13 and prostate-cancer risk. The New England journal of medicine366,141–149, (2012). https://doi.org/10.1056/NEJMoa1110000
Akbari, M. R. et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J. Natl Cancer Inst. 104, 1260–1262. https://doi.org/10.1093/jnci/djs288 (2012).
Liu, J. et al. Identification of coding region SNPs from specific and sensitive mRNA biomarkers for the deconvolution of the semen donor in a body fluid mixture. Forensic Sci. Int. Genet. 52, 102483. https://doi.org/10.1016/j.fsigen.2021.102483 (2021).
Eskra, J. N. et al. A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer Prostatic Dis. 24, 220–232. https://doi.org/10.1038/s41391-020-00272-6 (2021).
Eskra, J. N. et al. Specific Detection of Prostate Cancer Cells in Urine by RNA In Situ Hybridization. J. Urol. 206, 37–43. https://doi.org/10.1097/ju.0000000000001691 (2021).
Lenka, G., Weng, W. H., Chuang, C. K., Ng, K. F. & Pang, S. T. Aberrant expression of the PRAC gene in prostate cancer. Int. J. Oncol. 43, 1960–1966. https://doi.org/10.3892/ijo.2013.2117 (2013).
Hu, W. Y. et al. Isolation and functional interrogation of adult human prostate epithelial stem cells at single cell resolution. Stem Cell. Res. 23, 1–12. https://doi.org/10.1016/j.scr.2017.06.009 (2017).
Guo, S. et al. GPSAdb: a comprehensive web resource for interactive exploration of genetic perturbation RNA-seq datasets. Nucleic Acids Res. 51, D964–d968. https://doi.org/10.1093/nar/gkac1066 (2023).
Hakimi, M. A., Dong, Y., Lane, W. S., Speicher, D. W. & Shiekhattar, R. A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes. J. Biol. Chem. 278, 7234–7239. https://doi.org/10.1074/jbc.M208992200 (2003).
Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953. https://doi.org/10.1016/j.cell.2004.12.012 (2004).
Shi, Y. J. et al. Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell. 19, 857–864. https://doi.org/10.1016/j.molcel.2005.08.027 (2005).
Lee, M. G., Wynder, C., Cooch, N. & Shiekhattar, R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437, 432–435. https://doi.org/10.1038/nature04021 (2005).
Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436–439. https://doi.org/10.1038/nature04020 (2005).
Perillo, B. et al. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 319, 202–206. https://doi.org/10.1126/science.1147674 (2008).
Huang, J. et al. p53 is regulated by the lysine demethylase LSD1. Nature 449, 105–108. https://doi.org/10.1038/nature06092 (2007).
Wang, J. et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41, 125–129. https://doi.org/10.1038/ng.268 (2009).
Metzger, E. et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 464, 792–796. https://doi.org/10.1038/nature08839 (2010).
Gocke, C. B. & Yu, H. ZNF198 stabilizes the LSD1-CoREST-HDAC1 complex on chromatin through its MYM-type zinc fingers. PLoS One. 3, e3255. https://doi.org/10.1371/journal.pone.0003255 (2008).
Liang, Y., Vogel, J. L., Narayanan, A., Peng, H. & Kristie, T. M. Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. Nat. Med. 15, 1312–1317. https://doi.org/10.1038/nm.2051 (2009).
Cai, W. et al. Targeting LSD1 in cancer: Molecular elucidation and recent advances. Cancer Lett. 598, 217093. https://doi.org/10.1016/j.canlet.2024.217093 (2024).
Hattori, Y. et al. Design, synthesis, and structure-activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects. Eur. J. Med. Chem. 239, 114522. https://doi.org/10.1016/j.ejmech.2022.114522 (2022).
Zhang, C., Wang, Z., Shi, Y., Yu, B. & Song, Y. Recent advances of LSD1/KDM1A inhibitors for disease therapy. Bioorg. Chem. 134, 106443. https://doi.org/10.1016/j.bioorg.2023.106443 (2023).
Song, Y., Zhang, H., Yang, X., Shi, Y. & Yu, B. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021. Eur. J. Med. Chem. 228, 114042. https://doi.org/10.1016/j.ejmech.2021.114042 (2022).
Baba, R. et al. Investigating the Therapeutic Potential of LSD1 Enzyme Activity-Specific Inhibition by TAK-418 for Social and Memory Deficits in Rodent Disease Models. ACS Chem. Neurosci. 13, 313–321. https://doi.org/10.1021/acschemneuro.1c00713 (2022).
Matsuda, S., Hattori, Y. & Kimura, H. Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism. Adv. Pharmacol. 102, 267–300. https://doi.org/10.1016/bs.apha.2024.10.017 (2025).
Baba, R. et al. LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. Sci. Adv. 7 https://doi.org/10.1126/sciadv.aba1187 (2021).
Zhang, L. et al. Inhibition of KDM1A activity restores adult neurogenesis and improves hippocampal memory in a mouse model of Kabuki syndrome. Mol. Ther. Methods Clin. Dev. 20, 779–791. https://doi.org/10.1016/j.omtm.2021.02.011 (2021).
Shen, L. et al. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy. J. Med. Chem. 67 (922–951). https://doi.org/10.1021/acs.jmedchem.3c02133 (2024).
Song, Y., Zhang, H., Yang, X., Shi, Y. & Yu, B. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021. European journal of medicinal chemistry228,114042, (2022). https://doi.org/10.1016/j.ejmech.2021.114042
Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98–w102. https://doi.org/10.1093/nar/gkx247 (2017).
Acknowledgements
We would like to express our gratitude to all those with whom we have had the pleasure of working on this and related projects.
Funding
No funding was received for this research.
Author information
Authors and Affiliations
Contributions
YL performed the experiments, conducted data analysis, and drafted the manuscript. CL designed and supervised the study. All authors reviewed and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics declarations
This study did not involve human or animal subjects, thus ethical approval was not required.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Liao, Y., Liu, C. LSD1 promotes prostate cancer cell proliferation by upregulating PRAC1 expression. Sci Rep (2026). https://doi.org/10.1038/s41598-026-42928-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-42928-8
